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ABSTRACT
Objective: This study examined adherence, discontinuation, and switch-
ing of rheumatoid arthritis (RA) biologics over a 1-year period after
initiation of the biologic treatment in Medicaid patients with RA.
Methods: The study sample consisted of Medicaid patients with RA in
California, Florida and New York who had newly initiated etanercept
(n = 1359), anakinra (n = 267), or inﬂiximab (n = 1012) between January
1, 2000 and December 31, 2002. Adherence (proportion of days covered
(PDC)  0.80), discontinuation (90-day continuous gap), and switching
(initiation of second biologic within 90 days of discontinuation date of
index biologic) were measured during the 12-month postindex biologic
initiation. Sensitivity analyses were conducted by varying the thresholds to
deﬁne these measures. Logistic regressions examined the factors associated
with RA biologic adherence and discontinuation.
Results: Anakinra users had the lowest mean PDC (0.36) and percent
adherent patients (11%) followed by etanercept users (mean PDC: 0.57;
% adherent: 32%) and inﬂiximab users (mean PDC: 0.64; % adherent:
43%). All three groups had high discontinuation rates (41% etanercept,
76% anakinra, and 41% inﬂiximab). Few patients who discontinued the
index biologic switched to another biologic. Logistic regressions found
that patients in Florida had lower odds of being adherent and higher odds
of discontinuing their index biologic than patients in California. Anakinra
users had lower odds and inﬂiximab users had higher odds of being
adherent than etanercept users. Anakinra users had higher odds of discon-
tinuation than etanercept users.
Conclusion: This study highlights the poor adherence to and premature
discontinuation without concurrent switching of RA biologics that should
raise concern for clinicians as well as payers.
Keywords: adherence, biologics, discontinuation, Medicaid, rheumatoid
arthritis.
Introduction
Rheumatoid arthritis (RA) is a debilitating chronic inﬂammatory
disease of the joints that affects approximately 1% of the popu-
lation [1]. RA adversely affects daily living and functional status,
with 33% of sufferers unable to work 5 years after disease onset.
RA also is associated with lifespan reduction of 5 to 10 years [2].
Biological treatments represent promising advances for indi-
viduals with RA, and have been associated with signiﬁcant
improvement in outcomes including reduction in pain, joint swell-
ing, serologic inﬂammatory indices, and rates of radiologic
damage [3]. There has been a rapid growth in the availability of
such new treatments for RA, with eight biologic therapies to treat
RA approved by the US Food and Drug Administration over the
past 10 years [4–11]. Nevertheless, the potential therapeutic
beneﬁts of biologics demonstrated in clinical trials may be under-
mined by poor adherence and early discontinuation of treatment
(i.e., nonpersistence) in clinical practice. In this time of growing
demands on limited health-care resources, poor adherence further
strains these resources because effectiveness of the incomplete
treatment may be low to none whereas the costs incurred for these
expensive treatments are high. Hence, nonadherence also raises
concerns for payers who are responsible for the high costs of these
agents as well as the medical costs ensuing from the progression of
disease and need for more aggressive treatment due to non-
adherence. Therefore, an assessment of the adherence to and
persistence on RA biologics is essential to understanding the costs
and effectiveness of these therapies in the real-world setting.
Few studies have examined adherence to and/or persistence
on biologics in RA patients in the United States [12–18]. This is
particularly surprising given the ﬁrst availability of these biolog-
ics on the US market over a decade ago and wide accessibility to
insurance claims databases permitting relatively quick and inex-
pensive analyses of medication use patterns in large populations.
Furthermore, a majority of these studies have focused on patients
from large US private health plans or managed care organiza-
tions which generally exclude poorer, sicker, disabled, or older
patients covered under the Medicaid or Medicare programs.
Only one study to date has examined biologic use in Medicaid
patients with RA [13]. Nevertheless, the data in this study were
limited to the single state of Tennessee and hence its results may
not generalize to Medicaid enrollees in other states. Because the
Medicaid population comprises a large part of our public payer
health system as well as tends to be underrepresented in clinical
trials, it is important to examine adherence to and discontinua-
tion of RA biologics in such patients.
This study used administrative claims data from three large
state Medicaid programs to examine adherence, discontinuation,
and switching of RA biologics over a 1-year period after initia-
tion of the biologic treatment in Medicaid patients with RA.
Methods
Data Source
We used data from the Medicaid Analytic Extract (MAX) ﬁles
for the states of California (CA), Florida (FL), and New York
(NY). MAX ﬁles are state Medicaid research ﬁles containing
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beneﬁciary-level enrollment, diagnoses, and medical and pre-
scription utilization and expenditure data on a calendar year
basis. MAX ﬁles include one ﬁle with annual enrollment infor-
mation and four claim ﬁles (inpatient, other therapy, long-term
care, prescription drugs). Because Medicare is the primary payer
for dual eligibles (i.e., elderly and with disability patients with
Medicaid and Medicare coverage), Medicare Parts A and B
claims data were linked to the MAX ﬁles for the dual eligibles to
supplement their health-care services captured in the MAX ﬁles.
Medicare-linked MAX ﬁles were obtained from 1999 to 2003
(the latest available data at the time of the analysis).
Study Sample
The study sample consisted of noninstitutionalized fee-for-service
Medicaid patients with RA who had newly initiated a biological
agent between January 1, 2000 and December 31, 2002. During
this period, the two biologics that were approved and widely
used were inﬂiximab and etanercept. Anakinra was also available
during this time frame, although less frequently used. Hence, the
sample included patients newly initiating one of these three bio-
logics. These biologics were covered under all three state Med-
icaid programs, with minimal copayments ranging from $0 (FL)
to $2 (NY). Only CA required prior authorization for these
biologics; however, the requirement was waived if the biologic
was administered in the physician’s ofﬁce.
The date of the ﬁrst medical or prescription claim indicating
use of a biological between January 1, 2000 and December 31,
2002 was denoted as the index date. Patients were required to
have continuous eligibility under fee-for-service Medicaid in the
12-month preindex and 12-month postindex dates. A biological
agent was considered newly initiated (i.e., the “index biologic”)
based on the absence of previous use of any RA biologic in the
12-month preindex date. Patients were required to have at least
one inpatient or two outpatient diagnoses of RA (International
Classiﬁcation of Diseases-9-Clinical Modiﬁcation codes 714.xx)
across Medicaid or Medicare claims in the 12-month preindex
date. The 12-month period postindex date was treated as the
follow-up period over which outcomes of adherence and discon-
tinuation to the index biologic drug were estimated.
Adherence
Adherence was deﬁned using the proportion of days covered
(PDC), measured as the number of days covered with biologic
divided by the ﬁxed time interval of 365 days from date of index
biologic therapy initiation (i.e., 12-month postindex) [19].
Etanercept and anakinra were subcutaneous self-injectable
biologics taken twice weekly (25 mg) and daily (100 mg), respec-
tively. These were dispensed via the pharmacy and hence identi-
ﬁed from the prescription claims using National Drug Codes.
The “days supply” ﬁeld available on these claims was used to
identify covered days. These comprised the time between the date
of prescription ﬁll and the end date of the prescription (i.e., the
ﬁll date plus the days’ supply of the prescription). Only if a reﬁll
for the same biologic occurred before the end date of the previous
prescription and the number of overlap days was equal to or
fewer than the number of days permitted under the state Med-
icaid program-speciﬁc early reﬁll policies (i.e., reﬁlls permitted
only 2 days before previous prescription expires in FL and only
after 75% of the previous prescription is used for CA and NY
[e.g., 7 days for a 28-day prescription]), the days’ supply for the
new prescription was appended to the end date of the previous
prescription. If the end date of the last prescription ﬁll ran past
the last day of the 12-month follow-up period, then it was
truncated at the last date of the follow-up period.
Inﬂiximab is a biologic requiring intravenous infusion usually
for up to 4 hours in a physician’s clinic or outpatient hospital
setting, and hence identiﬁed from the medical claims using the
Healthcare Common Procedure Coding System code J1745.
Unlike the prescription claims for etanercept and anakinra, there
is no “days supply” data ﬁeld associated with intravenous
administrations of inﬂiximab recorded in the medical claims.
Therefore, to calculate the PDC measures for inﬂiximab, we had
to “assign” days supply for each inﬂiximab administration. We
assigned days supply based on inﬂiximab’s recommended dosing
schedule and individual dosing patterns identiﬁed for each
patient in the data (Table A1 at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH13i6_Li-Doshi.asp).
Unlike the pharmacy-dispensed self-injectables in which an
overlap (at a maximum of 7 days) because of an earlier reﬁll
would result in the days’ supply being appended at the end of the
previous prescription, we did not append the days’ supply for an
inﬂiximab administration received earlier than the dosing sched-
ule (e.g., at week 5.5 instead of week 6) to the expected end date
of the previous administration. Instead, the end date of the
previous administration was truncated to the start date of the
next administration. This was because an earlier infusion of
inﬂiximab is not the same as an earlier reﬁll of self-injectables,
wherein the previous stock of syringes would be ﬁrst exhausted
before the new reﬁll syringes are started to be used by the
patients.
We examined PDC for all three index biologic medications in
subgroups of patients without any diagnosis of speciﬁc types of
cancers and/or infections that might require the biologic to be
withheld or discontinued in the postindex period and hence
reduce the adherence rates. We also examined PDC in subgroups
of patients who may be using these biologic medications in
combination with oral disease-modifying antirheumatic drugs
(DMARDs) identiﬁed as those ﬁlling an oral DMARD prescrip-
tion on or within 30 days of the index biologic initiation date. As
part of sensitivity analysis, we extended the 30-day window to 90
days to deﬁne combination use with oral DMARDs. Finally, we
also explored the subgroup of early-stage RA patients in our
sample. Given the lack of clinical measures such as RA disease
activity, it is difﬁcult to reliably identify early-stage RA patients
in claims data. Nevertheless, we used a proxy by examining a
subset of patients who were likely newly diagnosed RA patients
in the 12-month preindex period. We identiﬁed such patients by
limiting our study sample to those who did not have claims-based
evidence of any RA diagnosis or oral DMARDs ﬁlled in the ﬁrst
6 months of the 12-month preindex date.
In addition to using a continuous measure of PDC, we also
created a binary indicator of whether the patient was adherent or
not based on a PDC  0.80, a cutoff commonly used in medica-
tion adherence studies including those examining RA biologics
[12,14,17]. Nevertheless, because this is an arbitrary cut point
we also conducted sensitivity analysis using alternative cutoffs of
PDC  0.70 and 0.90.
Discontinuation
Although the PDC measures indicate the extent of medication
availability in the observed period, it does not indicate whether
measures less than 1.0 indicate gaps in use that were dispersed
over the time period, or existed for a continuous period, or
whether the patient completely discontinued therapy. Each of
these scenarios has different clinical implications. Hence, to
further understand the RA biologics use, we also measured the
outcome of discontinuation generally deﬁned in the literature as
a continuous gap of a prespeciﬁed length in the use of the
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biologic. Our primary outcome of discontinuation was a
dichotomous measure indicating the incidence of a
90-consecutive-day period without a biologic. Again, such con-
tinuous periods were calculated based on the prescription ﬁll date
and days’ supply for the index biologic prescriptions in the
12-month follow-up period. We also measured the time to dis-
continuation deﬁned as the time from index date to the beginning
date of the ﬁrst 90-consecutive-day gap. Even though some
patients may reinitiate the biologic agent after the ﬁrst
90-consecutive-day gap, for the purpose of this study they were
deﬁned as having discontinued the biologic agent. This deﬁnition
of discontinuation, based on a deﬁned gap in therapy, has been
used in previous studies of RA biological use [13,15–18]. Nev-
ertheless, the length of the gap used to deﬁne discontinuation of
RA biologics has varied in terms of 30 days [16–18], 60 days
[15], or 90 days [13] across studies. Hence, we conducted a
sensitivity analysis of discontinuation based on continuous gaps
of 30, 60, 90, and 120 days.
Switching
We also separately measured whether patients who discontinued
the index biologic switched to another biologic. Switching was
deﬁned as the ﬁrst occurrence of a prescription ﬁll or adminis-
tration of a second (different) biologic medication within 90 days
of the last day supply of the index biologic and no evidence of use
of the second (switched-to) biologic in the 120 days before dis-
continuation date of the index biologic. The latter criterion is
important to help identify true switches by ensuring that the
patient was not already using the second biologic before discon-
tinuing the index biologic. In sensitivity analyses, we used a
continuous gap of 120 days to deﬁne discontinuation of the
index biologic and scanned this 120-day period for the occur-
rence of a prescription ﬁll or administration of a second (differ-
ent) biologic medication. Because the self-injectable adalimumab
was approved during the follow-up period in our study (i.e.,
December 2002), we also examined switching to this biologic in
addition to inﬂiximab, etanercept, and anakinra.
Other RA Biologic or DMARD Use
We also measured the use of any other biologic during the
12-month postindex date in all patients (regardless of whether
they discontinued the index biologic or not and the timing of
their switch). We similarly measured use of other oral DMARDs,
particularly methotrexate, which is indicated in combination
with inﬂiximab during the 12-month period postindex date.
Statistical Analysis
Multivariable analyses were conducted to examine the sociode-
mographic and clinical factors associated with RA biologic adher-
ence and persistence. Sociodemographic variables included
patients’ age, sex, race, dual-eligibility status, state, and year of the
index date. Because measures of RA serologic status or functional
status are not available in claims data we included binary indica-
tors for any hospital admission with RA as the primary diagnosis
and history of use of other prescribed RA drug classes (oral
DMARDs, steroids, opioids, nonsteroidal antiinﬂammatory
drugs, cyclooxygenase-2 inhibitors, acetaminophen-containing
products, salicylate-containing products, and tramadol) in the
12-month preindex period as amarker of RA severity. In addition,
we also included the prescription drug hierarchical condition
category (RxHCC) risk score measured in the 12-month preindex
period as an overall measure of comorbidity and prescription
burden, with a higher score indicating a higher burden [20]. This
single risk score accounts for the presence of 184 medical condi-
tions based on the diagnoses recorded on beneﬁciaries’ medical
claims and has been widely used for adjusting potential confound-
ing in studies of medical and drug use [21–23]. Finally, all models
included dummy variables for the index biologics (etanercept,
inﬂiximab, or anakinra). Logistic regression was used for binary
outcomes such as percent adherent (i.e., PDC  0.80) and discon-
tinuation. All analyses were conducted in SAS version 9.1.3 (SAS
Institute, Cary, NC) and STATA version 9.0 (StataCorp LP,
College Station, TX).
Results
Sample Characteristics
A total of 5390 users of etanercept, anakinra, and inﬂiximab
with an RA diagnosis were identiﬁed between 2000 and 2002. Of
these 3072 had continuous eligibility under fee-for-service Med-
icaid in the 12-month preindex and 12-month postindex dates.
After applying additional sample selection criteria, the ﬁnal
sample included 2638 patients with 1359 patients identiﬁed in
the etanercept group, 267 patients in the anakinra group, and
1012 in the inﬂiximab group (Table 1). The mean age of patients
was similar in the etanercept (54.9 years) and the anakinra (55.9
years) groups, but was signiﬁcantly higher in the inﬂiximab
group (63.3 years, P < 0.05). About twice as many patients were
over the age of 65 in the inﬂiximab group (57%) compared to the
etanercept group (29%, P < 0.05), whereas there were no differ-
ences between the anakinra and etanercept groups. Nearly 90%
of the patients in all three biologic groups were female and
around half of the patients were white. The percentage of
patients who were dually eligible for Medicaid and Medicare was
signiﬁcantly higher in the inﬂiximab group (96%, P < 0.05) rela-
tive to the etanercept group (53%) and anakinra group (58%).
Between 8% and 12% of the patients had a cancer diagnosis, and
39% to 49% of the patients had an infection diagnosis across the
three groups that may have required RA biologic treatment to be
put on hold or discontinued in the 12-month postindex period.
Inﬂiximab users were signiﬁcantly more likely to have these
diagnoses relative to etanercept users (P < 0.05), whereas the
rates in the anakinra group were similar to the etanercept group.
All three groups had high rates of other RA medication use in the
12-month preindex period; whereas the rates of use of different
RA drug classes were signiﬁcantly different across the groups (see
Table 1). Between 82% and 86% of the patients used an oral
DMARD (with 55–64% speciﬁcally using methotrexate). Use of
systemic corticosteroids (71–78%) and opioids (54–61%) was
also high across the groups. The inﬂiximab (1.0) and anakinra
(0.89) groups had signiﬁcantly higher mean RxHCC risk scores
than the etanercept group (0.81).
Adherence
Table 2 and Figure 1 present measures of adherence to each of
the index biologic medications. A majority of the etanercept
(90%) and inﬂiximab (96%) users had more than one ﬁll or
administration in the 12-month postindex period; however, 22%
of anakinra users had no additional ﬁlls after the index biologic
during this time frame (data not shown). Hence, over the
12-month follow-up period, anakinra users had the lowest mean
PDC (0.36) and the lowest percentage (10.5%) of adherent
patients (based on PDC  0.80) across all three groups
(P < 0.05). The mean PDC for etanercept users was also low at
0.57, with only about one-third (32%) of etanercept users being
coded adherent (based on PDC  0.80). Inﬂiximab users had the
highest PDC (0.64); however, only 43% were deemed adherent
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(based on PDC  0.80). The use of a higher cutoff than 0.80 to
deﬁne patients as adherent (i.e., PDC  0.90) resulted in a large
relative decrease of approximately 40% to 50% across all three
biologics whereas decreasing the cutoff (i.e., PDC  0.70)
resulted in an absolute increase of only about 4% to 10% in the
percent adherence rates for etanercept and inﬂiximab and only
5% for anakinra (Fig. 1).
Table 2 also displays mean PDC measures for all three index
biologic medications in subgroups of patients without any diag-
nosis of a cancer and/or infection that might require the biologic
to be withheld or discontinued in the postindex period. The mean
PDCs in these subgroups were only slightly higher than those
reported in the overall sample. Similarly, the mean PDCs in the
subgroups of patients using oral DMARDs on or within 30 days
(or 90 days) of the index biologic initiation date were only
marginally higher than the overall sample. The mean PDC in the
newly diagnosed RA subgroup was slightly lower for both etan-
ercept (0.53) and inﬂiximab (0.58), and slightly higher for anak-
inra (0.46).
Discontinuation
Table 3 presents the measures of discontinuation with and
switching from the three index biologic medications over a ﬁxed
12-month follow-up period. Anakinra had the highest discon-
tinuation rates (70% with 120 days continuous gap and 89%
with 30 days continuous gap). Etanercept and inﬂiximab had
comparable discontinuation rates which were substantially lower
than those for anakinra. Nevertheless, about one-third of the
users in both groups had a continuous gap of 120 days and
about two-thirds had a continuous gap of 30 days. The mean
time to discontinuation among those who discontinued across
the three groups ranged between 93 days and 123 days across all
measures.
Switching
Among patients who discontinued the index biologic for 120
days over a ﬁxed 12-month period, very few newly initiated
Table 1 Characteristics of new users of biologics among Medicaid
patients with rheumatoid arthritis (RA)
Characteristics Etanercept Anakinra Inﬂiximab
N 1359 267 1012
Sociodemographic
Age (mean, SD) 54.9 (16.6) 55.9 (14.3) 63.3 (13.6)*
44 (%) 23.3 21.7 9.7*
45–54 (%) 21.3 21.3 14.4
55–64 (%) 26.4 28.5 19.4
65–69 (%) 10.0 10.5 20.3
70–79 (%) 14.2 14.6 28.5
80 (%) 4.9 3.4 7.8
Male (%) 11.6 8.2 12.4
Race/ethnicity (%)
White 45.8 47.9 49.6*
Black 12.6 14.6 13.0
Hispanic 18.3 20.2 13.9
Other 13.9 10.9 22.8
Missing 9.4 6.4 0.6
Dual eligible status (%) 53.3 58.1 96.3*
Year index biologic prescription
ﬁlled (%)
2000 64.3 0.0* 21.4*
2001 24.4 1.9 35.3
2002 11.3 98.1 43.3
State Medicaid program (%)
CA 48.0 37.1* 74.4*
FL 18.3 21.7 13.6
NY 33.7 41.2 12.0
Clinical
Any cancer diagnosis requiring
RA biologic treatment to be
put on hold or discontinued
in 12-month postindex (%)
7.8 9.7 12.4*
Any infection diagnosis
requiring RA biologic
treatment to be put on
hold or discontinued in
12-month postindex (%)
39.4 43.1 49.4*
Any inpatient stay with
primary diagnosis of RA (%)
6.2 4.5 4.6
Any RA prescription use by drug
class (%)
Any pain-related prescription 98.9 98.5 97.6*
Oral DMARDs 83.4 82.0 85.5
Methotrexate 56.1 54.7 64.4*
Steroids 76.5 77.9 71.2*
Opioids 53.6 61.0* 55.4
NSAIDs 53.1 41.2 41.3*
COX-2 inhibitors 61.0 63.7 62.1
Acetaminophen containing
products
60.5 64.0 60.0
Salicylate containing products 11.4 16.5* 14.1*
Tramadol 15.5 22.5* 19.2*
RxHCC risk score 0.81 0.89* 1.00*
*Signiﬁcantly different from etanercept group at P < 0.05.
Note:All measures were calculated in the 12-month preindex period except for any cancer
diagnosis and any infection diagnosis requiring RA biologic treatment to be put on hold or
discontinued, which were measured in the 12-month postindex period.
CA, California; COX-2, cyclooxygenase-2; DMARDs, disease-modifying antirheumatic drugs;
FL, Florida; NSAIDs, nonsteroidal antiinﬂammatory drugs; NY, NewYork; RxHCC, prescrip-
tion drug hierarchical condition category.
Table 2 Adherence to index biologic over 12-month follow-up among
Medicaid patients with rheumatoid arthritis (RA)
Etanercept Anakinra Inﬂiximab
All patients (N) 1359 267 1012
Mean PDC over ﬁxed 12-month
follow-up period
0.57 0.36* 0.64*
Subgroups of patients without cancer/
infection diagnoses requiring biologic
to be put on hold or discontinued
Patients without cancer diagnoses (N) 1253 241 887
Mean PDC over ﬁxed 12-month
follow-up period
0.57 0.36* 0.64*
Patients without infection diagnoses
(N)
823 152 512
Mean PDC over ﬁxed 12-month
follow-up period
0.58 0.36* 0.67*
Patients without infection or cancer
diagnoses (N)
772 139 467
Mean PDC over ﬁxed 12-month
follow-up period
0.58 0.37* 0.68*
Subgroups of patients with oral
DMARD use in combination with
index biologic
Patients with oral DMARD ﬁll on or
within 30-days of index biologic date
(N)
523 111 463
Mean PDC over ﬁxed 12-month
follow-up period
0.59 0.42* 0.68*
Patients with oral DMARD ﬁll on or
within 90-days of index biologic date
(N)
788 158 676
Mean PDC over ﬁxed 12-month
follow-up period
0.59 0.38* 0.67*
Subgroup of newly diagnosed RA
patients
Patients without a RA diagnosis and
oral DMARD in the ﬁrst half of the
1-year period before index biologic
date (N)
102 22 88
Mean PDC over ﬁxed 12-month
follow-up period
0.53 0.46 0.58
*Signiﬁcantly different from etanercept group at P < 0.05.
DMARD, disease-modifying antirheumatic drug; PDC, proportion of days covered.
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another biologic over this 120-day period, particularly among
discontinuers of etanercept or inﬂiximab. Among discontinuers
of anakinra, about 9% switched to etanercept, and 4% each to
inﬂiximab and adalimumab. Similar rates of switching were
observed among patients who discontinued the index biologic for
90 days over a ﬁxed 12-month period.
Other RA Biologic or DMARD Use
An examination of other RA biologic use in the 12-month postin-
dex biologic initiation indicates that very few of the etanercept
and inﬂiximab users received other biologic therapies. On the
other hand, 21% of the anakinra patients received etanercept,
7% received inﬂiximab, and 16% received adalimumab at some
point during the 12-month post-anakinra initiation. Also, a
majority of the patients in all three index biologic groups ﬁlled at
least one oral DMARD prescription within 12-month postindex
date (78, 77, and 87% for etanercept, anakinra, and inﬂiximab,
respectively). Speciﬁcally, a large percentage of patients received
methotrexate over this 1-year period (48, 45, and 63% for etan-
ercept, anakinra, and inﬂiximab, respectively).
Factors Associated with Adherence and Discontinuation
Table 4 presents the logistic regression results on factors associ-
ated with adherence (PDC  0.80) and discontinuation (90
days continuous gap) among index biologic users over a ﬁxed
12-month follow-up period. Few demographic or clinical vari-
ables were signiﬁcantly associated with index biologic adherence
or discontinuation. As compared to Whites, patients of “other”
race had higher odds of adherence and lower odds of discontinu-
ation. Medicaid patients in FL were less likely to be adherent
(OR 0.67; 95% CI 0.52–0.86) and more likely to discontinue
(OR 1.27; 95% CI 1.01–1.61) their index biologic as compared
to patients in CA. Patients who had used oral DMARD in the
12-month preindex period were more likely to be adherent (OR
1.27; 95% CI 1.00–1.62) and less likely to discontinue their
index biologic (OR 0.65; 95% CI 0.52–0.81). In addition,
patients who had previously used steroids in the 12-month pre-
index had signiﬁcantly higher odds of discontinuation (OR 1.29;
95% CI 1.07–1.56). Finally, anakinra users (OR 0.27; 95% CI
0.17–0.42) were less likely and inﬂiximab users (OR 1.47; 95%
CI 1.18–1.83) were more likely to be adherent than etanercept
users. As compared to etanercept users, anakinra users were also
more likely to discontinue (OR 3.97; 95% CI: 2.78–5.66)
whereas the odds of discontinuation among inﬂiximab users
were no different.
Discussion
This study was a comprehensive evaluation of the adherence,
discontinuation, and switching patterns of etanercept, anakinra,
and inﬂiximab among Medicaid enrollees with RA. Unlike clini-
cal trial data, this study provides valuable insights on the patterns
of use of newly initiated RA biologics in routine clinical practice
and allows for the evaluation of biologic adherence and persis-
43%
32%
17%
15%
11%
6%
53%
43%
26%
0%
10%
20%
30%
40%
50%
60%
PDC >=0.70 PDC >=0.80 PDC >=0.90
Etanercept
Anakinra
Infliximab
Figure 1 Percent adherent to index biologic over
12-month follow-up among Medicaid patients with
rheumatoid arthritis. Note: PDC = proportion of
days covered. Percent adherent rates (PDC
0.70, PDC 0.80, and PDC 0.90) for the anak-
inra and inﬂiximab groups were signiﬁcantly differ-
ent from the etanercept group at P < 0.05.
Table 3 Discontinuation and switching from index biologic over
12-month follow-up among Medicaid patients with rheumatoid arthritis
(RA)
Etanercept Anakinra Inﬂiximab
N 1359 267 1012
Discontinuation
Continuous gap of 120 days (%) 34.5 70.0* 33.6
Mean time to gap (days) 97 93 111*
Continuous gap of 90 days (%) 40.7 76.0* 40.9
Mean time to gap (days) 105 101 122*
Continuous gap of 60 days (%) 50.0 82.0* 48.3
Mean time to gap (days) 109 105 123*
Continuous gap of 30 days (%) 67.9 88.8* 65.3
Mean time to gap (days) 105 98 111*
Switching among discontinuers
N with continuous gap of 120 days† 469 187 340
% switch to etanercept NA 9.1 4.4
% switch to anakinra 1.5 NA 0.9
% switch to inﬂiximab 2.8 4.3 NA
% switch to adalimumab 0.2 4.3 0.3
N with continuous gap of 90 days† 553 203 414
% switch to etanercept NA 8.3 4.1
% switch to anakinra 1.4 NA 1.0
% switch to inﬂiximab 2.5 3.4 NA
% switch to adalimumab 0.2 5.4 0.5
Other RA biologic or DMARD use in
12-month postindex
1359 267 1012
RA biologic use†
% etanercept use NA 21.3 4.6
% anakinra use 1.5 NA 1.0
% inﬂiximab use 3.5 7.1 NA
% adalimumab use 0.7 15.7 1.8
Oral DMARD use
% oral DMARD use 78.0 77.2 86.7*
% methotrexate use 47.6 44.6 63.2*
*Signiﬁcantly different from etanercept group at P < 0.05.
†Tests of statistical signiﬁcance not conducted.
DMARD, disease-modifying antirheumatic drug; NA, not applicable.
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tence among RA patients in three large state Medicaid programs
whose combined enrollment represents approximately one-third
of the total Medicaid enrollment in the United States [24].
We ﬁnd that adherence to the individual biologics was low
and a substantial proportion of patients on each of the three
biologics discontinued their use within 12 months of initiation
without switching to other biologics during the course of
follow-up over 1 year. The lack of information on reasons for
nonadherence in administrative claims data makes it difﬁcult to
assess whether patients were interrupting or discontinuing bio-
logic use for clinically appropriate reasons such as incidence of
adverse events or lack of treatment response. Hence, we cannot
expect an adherence rate of 1.0 in the sample. Nevertheless, we
found very similar low rates of adherence (mean PDC: 0.37–
0.68) in the sample even after excluding patients who developed
infections or cancers after biologic treatment initiation, both
potential reasons for interrupting or discontinuing biologic use.
Also, if the high discontinuation rates (90-day continuous gap:
41–76%) were due to patients not having a clinical response to
the index biologic, then ideally one should have observed con-
current switching to another biologic. Nevertheless, our results
indicated little switching to alternatives among the three biologic
users. These ﬁndings highlight several missed opportunities in
maximizing the potential therapeutic beneﬁts of biologics in real-
world settings.
In general, our study found lower adherence and higher dis-
continuation rates for these biologics than those reported in the
literature. For instance, studies examining adherence to etanercept
over a ﬁxed observation period of 1 year have reported the
medication possession ratio (MPR) measure (calculated as the
total number of days of medication supplied within a period,
divided by the number of days in the period) ranging from 0.65 to
0.83 [12–14,17]. Also, the rates of etanercept discontinuation
(50% with 30-day gap [18] and 45% with 60-day gap [6]) were
lower than those reported in our study. Similarly, mean adherence
to inﬂiximab over 1 year was much higher (MPR: 0.81) [12] and
its discontinuation rate much lower (37.8% with 60-day gap)
[15]. One explanation for these differences in ﬁndings may be that
all of these studies in the literature have been conducted in US
health plans comprising of privately insured enrollees. Clearly, our
study sample of Medicaid enrollees has a much lower socioeco-
nomic status than these commercially insured patients which has
also been correlated with poorer adherence [25]. Another expla-
nation for our lower adherence rates is the discordance in the
deﬁnitions of adherence and discontinuation. For instance, even
Grijalva et al., the only previous study of RA biologics using
Medicaid data [13], reported the MPR for etanercept at 0.83 and
inﬂiximab at 0.90, which is much higher than our reported PDC
measures for these two biologics. This is because as opposed to the
MPR measure in this and most other previous studies, our study
Table 4 Factors associated with RA biologic adherence and discontinuation over 12-month follow-up period after index date
Independent variables
Adherent (PDC 0.80) Discontinuer (90 days continuous gap)
Adjusted
odds ratio 95% CI
Adjusted
odds ratio 95% CI
Age
44 1.00 — 1.00 —
45–54 1.09 (0.82–1.46) 1.00 (0.76–1.30)
55–64 1.49* (1.13–1.95) 0.91 (0.71–1.18)
65–69 1.24 (0.90–1.72) 0.95 (0.69–1.29)
70–79 1.31 (0.97–1.78) 1.12 (0.83–1.49)
80 1.06 (0.69–1.63) 1.25 (0.84–1.87)
Male 1.11 (0.85–1.43) 1.08 (0.84–1.38)
Race/ethnicity
White 1.00 — 1.00 —
Black 0.95 (0.73–1.25) 1.14 (0.89–1.46)
Hispanic 1.02 (0.80–1.3) 0.80 (0.63–1.00)
Other 1.29* (1.02–1.63) 0.76* (0.60–0.96)
Missing 0.93 (0.62–1.42) 0.96 (0.65–1.40)
Dual eligible 1.07 (0.83–1.38) 1.07 (0.84–1.35)
Year index biologic prescription ﬁlled
2000 1.12 (0.88–1.41) 0.85 (0.68–1.07)
2001 0.98 (0.77–1.23) 0.88 (0.70–1.10)
2002 1.00 — 1.00 —
State Medicaid program
CA 1.00 — 1.00 —
FL 0.67* (0.52–0.86) 1.27* (1.01–1.61)
NY 0.89 (0.72–1.11) 1.21 (0.98–1.48)
Any inpatient stay with primary diagnosis of RA 0.93 (0.64–1.36) 1.02 (0.71–1.45)
Any RA prescription use by drug class
Oral DMARDs 1.27* (1.00–1.62) 0.65* (0.52–0.81)
Steroids 0.98 (0.80–1.19) 1.29* (1.07–1.56)
Opioids 1.00 (0.75–1.34) 1.04 (0.79–1.37)
NSAIDS 1.02 (0.86–1.21) 0.97 (0.82–1.14)
COX-2 inhibitors 1.12 (0.94–1.34) 0.98 (0.83–1.17)
Acetaminophen containing products 0.98 (0.73–1.31) 0.99 (0.75–1.32)
Salicylate containing products 1.02 (0.79–1.31) 1.06 (0.83–1.36)
Tramadol 1.02 (0.82–1.28) 1.04 (0.84–1.29)
RxHCC risk score 0.98 (0.79–1.21) 1.11 (0.91–1.36)
Index biologic
Etanercept 1.00 — 1.00 —
Anakinra 0.27* (0.17–0.42) 3.97* (2.78–5.66)
Inﬂiximab 1.47* (1.18–1.83) 0.96 (0.78–1.19)
*Statistically signiﬁcant at P < 0.05.
CA, California; COX-2, cyclooxygenase-2; DMARDs, disease-modifying antirheumatic drugs; FL, Florida; NSAIDs, nonsteroidal antiinﬂammatory drugs; NY, NewYork; PDC, proportion of days
covered; RxHCC, prescription drug hierarchical condition category.
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used the more conservative PDC measure which counts each day
in the 12-month observation period as coveredwith a days’ supply
of the medication or not (i.e., PDC would strictly be 1.0).
Because the MPR simply aggregates the total days’ supply of all
prescriptions ﬁlled during the observation period, it generally
overestimates adherence because of any overlapping prescriptions
resulting from an early ﬁll (i.e., MPR could potentially be >1.0).
Furthermore, Grijalva et al. examined adherence by “dividing the
aggregated number of days supply obtained during the episode by
the length of the episode, excluding the last prescription ﬁll [13].”
Use of the time interval between the ﬁrst and last prescription ﬁll
to deﬁne the observation period in the MPR results in an artiﬁcial
exclusion of the most nonadherent patients (i.e., those who only
had one prescription and then discontinued use). Also, patients
who used only two or three prescriptions during the year, all of
them consecutively without any gaps, would be coded as perfectly
adherent. Finally, Grijalva et al. did not describe how they applied
their MPR deﬁnition to measure adherence to inﬂiximab [13].
Because it is administered in the physician’s ofﬁce, inﬂiximab
claims appear in medical and not prescription claims data, and
hence lacks a variable on the days’ supply, which is needed to
calculate the traditional measures of adherence (e.g., MPR,
PDC) and discontinuation for outpatient prescription drugs
using prescription claims. In addition to using a more rigorous
measure (PDC) for biologic adherence compared to previous
studies, our study is also the ﬁrst to propose a comprehensive
method (Table A1 at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i6_Li-Doshi.asp) to develop a parallel
measure of adherence to infusion biologics such as inﬂiximab.
Our study found that anakinra had the lowest adherence and
highest discontinuation rates across all three biologics, followed
by etanercept and then inﬂiximab. The poor compliance with
anakinra may be because of its daily injection schedule, poor
efﬁcacy, and side-effect proﬁle. Two recent systematic reviews
have concluded that anakinra was less efﬁcacious, had a higher
incidence of injection site reactions, and was more likely to lead to
withdrawals due to adverse events compared to other biologics
like etanercept [26,27]. Our ﬁnding that inﬂiximab users were
more likely to be adherent than etanercept users is also consistent
with earlier literature [12–14]. Although both agents have similar
efﬁcacy, issues such as route and frequency of administrationsmay
inﬂuence patient treatment preferences and adherence. Some
patients, particularly older patients, may tend to prefer infusion
biologics like inﬂiximab, given the clinical assistance received in
terms of administration by a physician or nurse as opposed to the
subcutaneously injected biologics like etanercept that require
self-administration and need to be administered more frequently
[28,29]. On the other hand, visiting a physician’s ofﬁce to receive
a 4-hour infusion may be less preferable to others given the time
and travel costs involved. Unfortunately, administrative claims
data do not contain information on such factors and hence further
research is needed to better understand whyMedicaid patients are
more likely to be adherent to inﬂiximab as opposed to etanercept.
Another noteworthy ﬁnding of our study was the variations
in biologic adherence and discontinuation across state Medicaid
programs. Medicaid patients in FL were less likely to be adherent
and more likely to discontinue their index biologic as compared
to patients in CA even after controlling for demographic and
clinical characteristics. State Medicaid prescription policies are
unlikely to explain this ﬁnding because the FL program charged
no copayments and did not subject these biologics to prior autho-
rization or a preferred drug list. This raises the question of
whether state-level variation in physician practice patterns or
other regional health-care resources contribute to these ﬁndings.
It is also possible that patient characteristics such as disease
activity and radiographic progression which are not captured in
claims data are partly responsible for this observed variation
across states. Future research should examine state-level varia-
tion in the patterns of use of these biologic agents and the
potential factors contributing to this variation that are amenable
to interventions to improve adherence.
There are some limitations of this study that deserve
acknowledgment. First, the study used administrative claims data
which are collected for the purpose of payment rather than
research. The presence of a claim for a ﬁlled prescription for the
self-injectable does not indicate that the biologic was actually
taken by the patient as prescribed. On the other hand, a claim for
an administration of inﬂiximab does indicate, except for the
presumably rare case of fraudulent claims ﬁled by providers, that
this biologic was indeed taken by the patient given its infusion
form. Second, there were differences in baseline characteristics
across the three biologic groups. Even though multivariate
regressions were used to control for observed differences by
adjusting for baseline characteristics, it is likely that unobserved
confounders such as RA disease activity and disability also con-
tribute to the difference in adherence and discontinuation across
the three index biologics. Third, we were unable to evaluate
reasons for nonadherence or discontinuation because they are
not available in claims data. Nevertheless, we did evaluate adher-
ence in subgroups of patients without certain types of cancer or
infection diagnoses that could have resulted in withholding or
discontinuation of the biologic and found that it did not affect
our main adherence results. Fourth, our study sample was limited
to three state Medicaid programs and our results may not be
representative of other states or the entire Medicaid population.
Nevertheless, the CA, NY, and FL Medicaid programs do com-
prise a substantial proportion of the total Medicaid enrollment
(32% in FY 2006) [24]. Lastly, due to delays in MAX data
release, our data were limited to the periods from 1999 to 2003,
the latest available data at the time of the study. It is possible that
late-stage RA patients were more likely to receive biologics
during that time period whereas early stage RA patients are more
likely to receive biologics in current clinical practice. Our sub-
group analysis in newly diagnosed RA patients indicated that
adherence was slightly lower for both etanercept and inﬂiximab
and slightly higher for anakinra. Given that etanercept and inﬂix-
imab are more commonly used RA biologics, this ﬁnding high-
lights that adherence is likely to be lower among early-stage RA
patients. This may be either reﬂective of the disease coming under
control after a few months of biologic use and hence discontinu-
ation of the biologic or that patients with low disease severity are
less likely to be adherent. Nevertheless, this suggests that our
ﬁndings in the overall sample provide an upper bound on the
estimates of adherence among Medicaid patients in today’s clini-
cal practice.
In summary, this study highlights the poor adherence to and
premature discontinuation without concurrent switching of
inﬂiximab, etanercept, and anakinra among patients newly ini-
tiating these agents that should raise concern for clinicians and
payers alike. Future studies should evaluate the clinical and eco-
nomic consequences associated with such suboptimal patterns of
use of these highly effective but expensive biologic agents.
Source of ﬁnancial support: This study was supported by an investigator-
initiated research grant from Abbott Labs.
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